Carlyle and SK Capital Partners announced on May 30, 2025, that the tender offer to acquire all outstanding common stock of bluebird bio, Inc. expired as scheduled. The offer, which included options for $3.00 per share plus a contingent value right or $5.00 per share in cash, was not extended.
Equiniti Trust Company, LLC, the depositary for the Offer, advised that approximately 5,868,196 shares, representing about 59.8% of bluebird's outstanding common stock, were validly tendered and not withdrawn. This satisfies the majority tender condition for the acquisition.
With all conditions to the Offer now satisfied, the parties expect to consummate the acquisition on June 2, 2025, through a merger. This marks a significant step towards finalizing Carlyle's strategic investment in the gene therapy maker, bluebird bio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.